Pasithea Therapeutics names Kartik Krishnan as new Chief Medical Officer to lead PAS-004 clinical development.

Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer to oversee clinical development of PAS-004, a next-gen MEK inhibitor targeting neurofibromatosis type 1 (NF1). Dr. Krishnan brings over 20 years of experience, including work on the FDA-approved MEK inhibitor cobimetinib, which aligns with Pasithea's mission. His leadership is expected to advance PAS-004 through ongoing Phase 1 trials for NF1 and other rare diseases. This strategic hire aims to accelerate development and improve patient outcomes in rare and pediatric conditions.